References

Anthonisen N, Manfreda J, Warren C et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;106:196-204.

Anthonisen N. The British hypothesis revisited. *Eur Respir J* 2004; 23: 657-658.

Arbex M, De Souza Conceição G, Cendon S et al. Urban air pollution and chronic obstructive pulmonary disease-related emergency department visits. *J Epid Com Health* 2009 Oct; 63(10):777-83.

Aaron S, Angel J, Lunau M et al. Granulocyte Inflammatory Markers and Airway Infection during Acute Exacerbations of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2001; 163: 349-355.

Aaron S, Vandemheen K, Herbert P et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. *N Engl J Med*. 2003 Jun 26; 348(26):2618-25.

Agusti A. COPD, a multicomponent disease: implications for management. *Resp Med* 2005; 90: 670-682.

Bandi V, Apicella M, Mason E et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. *Am J Respir Crit Care Med*. 2001; 164(11):2114-2119.

Bandi V, Jakubowycz M, Kinyon C et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. *FEMS Immunol Med Microbiol.* 2003; 37(1):69-75

Banerjee D, Khair O, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. *Eur Respir J* 2004; 23: 685-691.

Baraldo S, Turato G, Badin C, Bazzan E, Beghe B, Zuin R, Clabrese F, Casoni G, Maestrelli P, Papi A, Fabbri LM, Saetta M. Neutrophilic infiltration within the airway smooth muscle in patients with COPD. *Thorax 2004;* 59:308-312.

Barcelo B, Pons J, Fuster A et al. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. *Clin and Exper Immun* 2006; 145: 474–479.

Barcelo B, Pons J, Ferrer JM et al. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. *Eur Respir J* 2008; 31: 555–562

Baker E, Janaway C, Philips B et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. *Thorax.* 2006; 61(4):284-289.

Barnes P, Celli B. Systemic manifestations and comorbidities in COPD. *Eur Respir J* 2009; 33: 1165–1185.

Bathoorn E, Liesker J, Postma D et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. *Int J Chron Obs Pulm Dis*. 2009; 4:101-9.

Berenson C, Wrona C, Grove L et al. Impaired Alveolar Macrophage Response to Haemophilus Antigens in Chronic Obstructive Lung Disease. *Am J Repir Crit Care Med* 2006; 174: 31-40.

Bhowmik A, Seemungal T, Sapsford R et al. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. *Thorax* 1998; 53: 953-956.

Bhowmik A, Seemungal T, Sapsford R et al. Relationship of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. *Thorax* 2000, 55: 114-120.

Bolton C, Ionescu A, Shiels K, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004; 170: 1286–1293.

Buist A, McBurnie M, Vollmer W et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. *Lancet* 2007; 370: 741-50.

Burge P, Calverley P, Jones P et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ* 2000; 320: 1297-1303.

Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 2003; 361: 449-456. (a)

Calverley P, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. *Eur Respir J* 2003; 22: 912-919. (b)

Calverley P, Anderson J, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med.* 2007; 356(8): 775-789.

Calverley P, Rabe K, Goehring U et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet* 2009 ; 374(9691):685-694.

Camargo C Jr, Ginde A, Clark S et al. Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. *Intern Emerg Med*. 2008; 3(4): 355-359.

Cameron RJ, de Wit D, Welsh TN et al. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. *Intensive Care Med*. 2006; 32(7): 1022-9.

Chan-Yeung M, Abboud R, DyBuncio A et al. Peripheral leucocyte count and longitudinal decline in lung function. *Thorax* 1988; 43: 462-466.

Chin C, Manzal L, Lehman E et al. Haemophilus influenza from patients with chronic obstructive pulmonary disease exacerbation induces more inflammation than colonizers. *Am J Respir crit Care Med* 2005; 172(1): 85-91.

Cho M, Boutaoui N, Klanderman B et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. *Nat Genet*. 2010 Mar; 42(3): 200-202.

Chu C, Chan V, Lin A et al. Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure. *Thorax* 2004; 59: 1020-1025.

Chung K, Adcock I. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. *Eur Respir J* 2008; 31: 1334–1356

Cowburn A, Condliffe A, Farahi N et al. Advances in neutrophil biology: clinical implications. *Chest* 2008; 134: 606-612.

Crooks S, Bayley D, Hill S et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. *Eur Respir J*. 2000; 15(2):274-80

Curran T, Coyle P, McManus T et al. Evaluation of real-time PCR for the detection and quantification of bacteria in chronic obstructive pulmonary disease. *FEMS Immunol Med Microbiol.* 2007; 50(1):112-8.

Daniels J, Snijders D, Graaff C et al. Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2010; 181: 150-157.

Davies L, Angus R, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet* 1999; 354(9177):456-60

Decramer M, Ruttenvan Molken M, Dekhuijzen P et al. Effects of N-Acetylcysteine on outcomes in COPD (BRONCHUS trial). *Lancet* 2005; 365: 155-160.

De Jong J, Van Der Belt-Gritter B, Koeter G et al. Peripheral blood lymphocyte cell subsets in subjects with chronic obstructive pulmonary disease: association with smoking, IgE and lung function. *Repir Med* 1997; 91: 67-76.

Dentener MA, Creutzberg EC, Schols AMW, Mantovani A, van't Veer C, Buurman WA, Wouters EFM. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. *Thorax* 2001; 56:721-726.

De Serres G, Lampron N, La Forge J et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. *J Clin Virol.* 2009; 46(2): 129-133.

Di Stefano A, Capelli A, mirco L et al. Severity of Airflow Limitation is Associated with Severity of Airway Inflammatin in Smokers. *Am J Resp Crit Care Med* 1998; 158: 1277-1285.

Domagała-Kulawik J, Hoser G, Dabrowska M, Chazan R. Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. *Respir Med*. 2007; 101(6):1338-1343

Dominici F, Peng R, Bell M et al. Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. *JAMA* 2006; 295(100): 1127-1134.

Donaldson G, Seemungal T, Bhowmik A et al. Effect of temparature on lung function and symptoms in chronic obstructive pulmonary disease. *Eur Respir J* 1999; 13: 844-849.

Donaldson G, Seemungal T, Bhowmik A et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. *Thorax* 2002; 57: 847-852.

Donaldson G, Seemungal T, Patel I *et al*. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. *Eur Respir J* 2003; 22: 931-936.

Donaldson G, Wilkinson T, Hurst J et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2005; 171: 446-457.

Donaldson G, Seemungal T, Patel I et al. Airway and Systemic Inflammation and decline in lung function in patients with COPD. *Chest 2005;*128:1995-2004.

Donaldson G, Wedzicha J. COPD Exacerbations 1: epidemiology. *Thorax 2006;* 61: 164–168.

Espy M, Uhl J, Sloan L et al. Real-Time PCR in clinical Microbiology: applications for Routine Laboratory Testing. *Clin Microbiol Rev* 2006; 19: 165-256.

Feary J, Rodrigues L, Smith C et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. *Thorax* 2010; 65(11): 956-962.

Fletecher C. Some recent advances in the prevention and treatment of chronic bronchitis and related disorders with special reference to the effects of cigarette smoking. *Proc R Soc Med*. 1965;58(11 Part 1):918-928.

Fletcher C, Peto R. The Natural History of Chronic airflow Obstruction. *BMJ* 1977; 1: 1645-1648.

Foster T, Miller J, Marton J et al. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. *COPD* 2006; 3(4): 211-218.

Fujimoto K, Yasuo M, Urushibata K et al. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. *Eur Respir J*. 2005; 25(4):640-646.

Gan W, Man S, Senthilselvan A et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. *Thorax* 2004; 59: 574-580.

Garcia-Aymerich J, Barreiro E, Farrero E et al. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). *Eur Respir J*. 2000 Dec;16(6):1037-1042.

Garcia-Aymerich J, Monsó E, Marrades R et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. *Am J Respir Crit Care Med.* 2001 Sep 15;164(6):1002-1007.

Garcia-Aymerich J, Farrero E, Félez M et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. *Thorax.* 2003; 58(2):100-105.

Garcia-Aymerich J, Lange P, Benet M et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. *Thorax.* 2006; 61(9):772-778.

Glezen W, Greenberg S, Atmar R et al. Impact of respiratory virus infections on persons with chronic underlying conditions. *JAMA* 2000; 283(4):499-505.

Gompertz S, O'Brien C, Bayley D et al. Change in bronchial inflammation during acute exacerbations of chronic bronchitis. *Eur Respir J* 2001; 17: 1112=-1119.

Griffiths T, Burr M, Campbell I et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation. *Lancet* 2000; 355: 362-368.

Greiner O, Day P, Bosshard P et al. Quantitative Detection of Streptococcus pneumoniae in Nasopharyngeal Secretions by Real-Time PCR. *J Clin Microbiol* 2001; 39: 3129-3134.

Groenevegen K, Postma D, Hop W et al. Increased systemic inflammation is a risk factor for COPD exacerbations. *Chest* 2008;133 (2):350-357.

Hendolin P, Markkanen A, Ylikoski J et al. use of Multiplex PCR for Simultaneous Detection of Four Bacterial Species in Middle Ear Effusions. *J Clin Microbiol* 1997; 35: 2854-2858.

Hendolin P, Paulin L, Ylikoski J. Clinically applicable multiplex PCR for four middle ear pathognes. *J Clin Microbiol* 2000; 38: 125-132.

Hill A, Campbell E, Hill S et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. *Am J Med* 2000; 109: 288-295. (a)

Hill A, Bayley D, Campbell E et al. Airways inflammation in chronic bronchitis: the effects of smoking and alpha-1-antitypsin deficiency. *Eur Respir J* 2000; 15: 886-890. (b)

Hnizdo E, Sullivan P, Bang K et al. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. *Am J Epid* 2002; 156(8): 738-746.

Hodge G, Nairn J, Holmes M et al. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. *Clin and Exp Immun* 2007; 150: 22-29.

Hodge S, Hodge G, Reynolds P et al. Increased production of TGF-beta and apoptosis of T lymphocytes isolated from peripheral blood in COPD patients. *Am J Physiol Lung Cell. Mol. Physiol.* 2003; 285: L492-499.

Hodge S, Hodge G, Homes M et al. Increased peripheral blood T-cell apoptosis and decreased Bcl-2 in chronic obstructive pulmonary disease. *Immun Cell Biol* 2005; 83: 160-166.

Hogg J, Chu F, Utokaparach S et al. The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease. *N Engl J Med 2004*; 350: 2645-2653.

Hurst J, Donaldson G, Wilkinson T et al. Epidemiological relationships between the common cold and exacerbation frequency in COPD. *Eur Respir J* 2005; 26: 846–852.

Hurst J, Donaldson G, Perera W et al. Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2006; 174: 867–874.

Hurst J, Donaldson G, Quint J et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2009; 179(5):369-374.

Hurst J. Upper airway 3: Sinonasal involvement in chronic obstructive pulmonary disease. *Thorax* 2010; 65:85-90.

Hurst J, Vestho J, Anzueto A et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. *N Eng J Med* 2010; 363:12, 1128-1138.

Hutchinson A, Ghimire A, Thompson M et al. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. *Respir Med.* 2007; 101(12):2472-2481.

Ischaki E, Papatheodorou G, Gaki E et al. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. *Chest.* 2007; 132(1): 164-169.

James A, Knuiman M, Divitini M et al. Associations between shite blood cell count, lung function, respiratory illness and mortality: the Busselton Health Study. *Eur Respir J* 1999; 13: 1115-1119.

Jensen E, Pedersen B, Narvestadt E et al. Blood eosinophil and monocyte counts are related to smoking and lung function. *Respir Med* 1998; 92: 63-69.

Jones P, Quirk P, Bayeystock C et al. A selfcomplete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. *Am Rev Repir Dis* 1992; 145: 1321-1327.

Jones P, Harding G, Berry P et al. Development and first validation of the COPD Assessment Test. *Eur Respir J*. 2009; 34(3): 648-654.

Jorgensen N, Schwarz P. Osteoporosis in chronic obstructive pulmonary disease patients. *Curr Opin Pulm Med* 2008; 14: 122–127.

Kais M, Spindler C, Kalin M et al. Quantitative detection of Sreptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in lower respiratory tract samples by real-time PCR. *Diagn Microbiol Infect Dis*. 2006 Jul; 55(3):169-178.

Kanner R, Anthoniesen N, Connett J et al. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. *Am J Respir Crit Care Med*. 2001; 164: 358-364.

Kherad O, Kaiser L, Bridevaux PO et al. Upper viral respiratory infection, biomarkers and chronic obstructive pulmonary disease (COPD) exacerbations. *Chest* 2010; 138(4):896-904.

Kim W, Kim W, Koh Y et al. Abnormal Peripheral Blood T-Lymphocyte subsets in a Subgroup of Patients With COPD. *Chest* 2002; 122: 437-444.

Kishimoto T. Interleukin-6: from basic science to medicine--40 years in immunology. *Annu Rev Immunol*. 2005; 23:1-21.

Knobloch J, Schild K, Jungck D et al. The T-helper cell type 1-immune response to gram negative bacterial infections is impaired in COPD. *Am J Respir Crit Care Med* 2011; 183(2):204-214.

Koch A, Gaczkowski M, Sturton G et al. Modification of surface antigens in blood CD8+ T-lymphocytes in CDOP: effects of smoking. *Eur Respir J* 2007; 29: 42–50.

Ko FW, Ip M, Chan PK, Chan MC et al. Viral etiology of acute exacerbations of COPD in Hong Kong. *Chest* 2007; 132(3):900-908.

Ko FW, Tam W, Wong TW et al. Chronic obstructive pulmonary disease: Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. *Thorax* 2007; 62: 780-785.

Kong X, Cho M, Anderson W et al. Genome-wide Association Study Identifies BICD1 as a Susceptibility Gene for Emphysema. *Am J Respir Crit Care Med*. 2011; 183(1):43-49.

Lehmann C, Wilkening A, Leiber D et al. Lymphocytes in the Bronchoalveolar Space Reenter the Lung Tissue by Means of the Alveolar Epithelium, Migrate to Regional Lymph Nodes and Subsequently Rejoin the Systemic Immune System. *The Anat Rec* 2001; 264: 229-236.

Leidy N, Wilcox T, Jones P et al. Standardizing Measurement of Chronic Obstructive Pulmonary Disease Exacerbations: Reliability and Validity of a Patient-reported Diary. *Am J Respir Crit Care Med*. 2011; 183(3): 323-329.

Ling S, Van Eeden S. Particulate matter air pollution exposure: role in the development and exacerbation of chronic obstructive pulmonary disease. *Int J COPD* 2009; 4: 233-243.

Mackay I, Arden K, Nitsche A. Real-time PCR in virology. *Nuc Acid Res* 2002; 30:1292-1305.

Mackay I. Real-time PCR in the microbiology laboratory. *Clin Microbiol Infect* 2004; 10: 190-212.

Majori M, Corradi M, Caminati A et al. Predominant Th1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J All *Clin Immun* 1999; 103: 458-462.

Man W, Kemp P, Moxham J et al. Skeletal muscle dysfunction in COPD: clinical and laboratory observations. *Clin Sci* 2009; 117: 251–264.

Mannino D, Buist A. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet* 2007; 370: 765–773.

Mannino D, Thorn D, Swensen A. et al. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. *Eur Respir J* 2008; 32: 962–269.

Marin A, Monso E, Garcia-Nunez M et al. Variability and effects of bronchial colonisation in patients with moderate COPD. *Eur Respir J* 2010; 35(2): 295-302.

Martinello RA, Esper F, Weibel C et al. Human metapneumovirus and exacerbations of chronic obstructive pulmonary disease. *J Infect.* 2006; 53(4):248-54.

McManus T, Marley A, Baxter N et al. High levels of Epstein-Barr virus in COPD. *Eur Respir J.* 2008; 31(6):1221-1226. (a)

McManus T, Marley A, Baxter N et al. Respiratory viral infection in exacerbations of COPD. *Respir Med*. 2008; 102(11):1575-80. (b)

McCrory D, Brown C, Gelfand S et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. *Chest* 2001; 119: 1190-1209.

McNicholas W. Chronic obstructive pulmonary disease and obstructive sleep apnoea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. *Am J Respir Crit Care Med*. 2009; 180: 692-700.

Miravitlles M, Marin A, Monso E et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. *Respir Res* 2010;11:58.

Monso E, Ruiz J, Rosell a et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. *Am J Respir Crit Care Med* 1995; 152: 1316-1320.

Monso E,Rrosell G, Bonet G et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. *Eur Repir J* 1999; 13: 338-342.

Murphy T, Brauer A, Aebi C et al. Antigenic Specificity of the Mucosal Antibody Response to Moraxella catarrhalis in Chronic Obstructive Pulmonary Disease. *Inf and Immun* 2005, 73: 8161-8166.

Murphy T, Brauer A, Schiffmacher A et al. Persistant colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004; 170(3): 266-272.

Niewoehner D, Erbland M, Deupree R et al. Effect of systemic glucocorticoids on exacerabtions of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. *N Engl J Med.* 1999; 340(25): 1941-1947.

Noguera A, Batle S, Miralles C et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. *Thorax* 2001; 56: 432-437.

Noguera A, Busquets X, Sauleda J et al. Expression of Adhesion Molecules and G Proteins in Circulating Neutrophils in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 1998; 158: 1664-1668.

Norwood RJ. A review of aetiologies of depression in COPD. *Int J of COPD* 2007; 2(4): 485–491.

O'Shaugnessy T, Ansari T, Barnes N et al. Inflammation in Bronchial Biopsies of FEV1. *Am J Resp Crit Care Med* 1997; 155: 852-857.

Papi A, Bellettato C, Braccioni F et al. Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations. *Am J Resp Crit Care Med* 2006; 173: 1114-1121.

Patel I, Seemungal T, Wilks M et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. *Thorax* 2002; 57: 759-764.

Patel I, Roberts N, Lloyd-Owen S et al. Airway epithelial inflammatory responses and clinical parameters in COPD. *Eur Respir J*. 2003; 22(1): 94-99.

Peltz M, Ioanas M, De Roux a et al. Reduced spontaneous apoptosis in peripheral bolood neutrophils during exacerbations of COPD. *Eur Rrepir J.* 2004; 23: 532-537.

Persson C, Uller L. Transepithelial exit of leucocytes: inflicting, reflecting or resolving airway inflammation? *Thorax* 2010; 65(12):1111-1115.

Pillai S, Kong X, Edwards L et al. Loci Identified by Genome-wide Association Studies Influence Different Disease-related Phenotypes in COPD. *Am J Respir Crit Care Med.* 2010; 182(12):1498-1505.

Pons J, Sauleda J, Ferrer JM et al. Blunted γδ T-lymphocyte response in chronic obstructive pulmonary disease. *Eur Respir J* 2005; 25: 441–446

Price LC, Lowe D, Hosker HS et al. UK National COPD Audit 2003: Impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. *Thorax.* 2006 ; 61(10): 837-842.

Quint J, Wedzicha W. The neutrophil in chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2007; 119: 1065-1071.

Ram F, Rodriguez-Rosin R, Granados-Navarrete A et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Databse Syst Rev* 2006:19: CD0004403.

Rascon-Aguilar I, Pamer M, Wludyka P, et al. Role of gastroesophageal reflux symptoms in exacerbations. *Chest* 2006; 130:1096–1101.

Rennard S, Schachter N, Strek M et al. Cilomilast for COPD: results of a 6 month, placebo controlled study of a potent, selective inhibitor of phosphodiesterase 4. *Chest* 2006; 129: 56-66.

Retamales I, Elliot M, Meshi B et al. Amplification of Inflammation in Emphysema and Its Association with Latent Adenoviral Infection. *Am J Resp Crit Care Med* 2001; 164: 469-472.

Ringshausen FC, Tan AY, Allander T et al. Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2009; 4: 111-117.

Rizkallah J, Man P, Sin D. Prevalence of Pulmonary Embolism in Acute Exacerbations of COPD. A systematic Review and Meta-analysis. *Chest* 2009; 135: 786–793.

Roberts C, Lowe D, Bucknall C et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. *Thorax* 2002; 57(2): 137-141.

Rohde G, Wiethege A, Borg I et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a cae-control study. *Thorax* 2003; 58: 37-42.

Rohde G, Borg I, Arinir U et al. Relevance of human metapneumovirus in exacerbations of COPD. *Respir Res.* 2005; 6: 150.

Rohde G, Borg I, Wiethege A et al. Inflammatory response in acute viral exacerbations of COPD. *Infection* 2008; 36(5): 427-433.

Rogers G, Daniels T, Tuck A et al. Studying bacteria in respiratory specimens by using conventional and molecular microbiological approaches. *BMC Pulmonary Medicine* 2009, 9:14. (a).

Rogers G, Carroll M, Bruce K. Studying bacterial infections through culture independent approaches. *J Med Microbiol* 2009; 58: 1401-1418. (b)

Roland M, Bhowmik A, Sapsford R et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2001; 56: 30-35.

Rosell A, Monso E, Soler N et al. Microbiologic Determinants of Exacerbation in Chronic Obstructive Pulmonary Disease. Arch Intern Med. 2005; 165: 891-897.

Royal College of Physicians, British Thoracic Society, and British Lung Foundation. *Report of the National Chronic Obstructive Pulmonary Disease Audit 2008: Clinical audit of COPD exacerbations admitted to acute NHS trusts across the UK.* London: Royal College of Physicians, 2008.

Saetta M, Di Stefano A, Turato G et al. CD8+ T-lymphocytes in the peripheral airwyas of smokers with chronic obstructive pulmonary disease. *Am J Resp Crit Care Med* 1998; 157: 822-826.

Saetta M, Turato G, Baraldo S et al. Goblet Cell Hyperplasia and Epithelial Inflammation in Peripheral Airways of Smokers with Both symptoms of Chronic

Bronchitis and Chronic Airflow Limitation. *Am J Resp Crit Care Med* 2000; 161: 1016-1021.

Saint S, Bent s, Vittinghoff E et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. *JAMA* 1995; 273: 957-960.

Salo P, Ortqvist A, Leinonen M et al. Diagnosis of bacteremic pneumococcal pneumonia by amplification of pneumolysin gene fragment in serum. *J Inf Dis*1995; 171: 479-482.

Salvi S, Barnes P. Chronic obstructive disease in non-smokers. *Lancet* 2009; 374: 733–743.

Saukkoriipi A, Palmu A, Kilpi T et al. Real-time quantitative PCR for the detection of Streptococcus pneumoniae in the middle ear fluid of children with acute otitis media. *Mol & Cell Probes* 2002; 16: 385-390.

Schols A, Broekhuizen R, Weling-Scheepers C et al. Body composition and mortality in chronic obstructive pulmonary disease. *Am J Clin Nutr*. 2005; 82(1):53-59.

Seemungal T, Stockley R, Calverlye P et al. Investigating new standards for prophylaxis in reduction of exacerbations: the INSPIRE study methodology. *COPD* 2007, 4(3): 177-183.

Seemungal T, Donaldson G, Paul E *et al*. Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 1998; 157:1418-1422.

Seemungal T, Harper-Owen R, Bhowmik A et al. Detection of rhinovirus in dnduced sputum at exacerbation of chronic obstructive pulmonary disease. *Eur Respir J* 2000; 16: 677-683.

Seemungal T, Donaldson G, Bhowmik A et al. Time Course and Recovery of Exacerbations in Patients with Chronic Obstructive Disease. *Am J Respir Crit Care Med* 2000; 161: 1608-1613.

Seemungal T, Harper-Owen R, Bhowmik A et al. Respiratory Viruses, Symptoms, and Inflammatory Markers in Acute Exacerbations and Stable Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2001; 164: 1618-1623.

Seemungal T, Wilkinson T, Hurst J et al. Long term macrolide therapy is associated with decreased COPD exacerbation frequency. *Am J Respir Crit Care Med* 2008; 178: 1139-1147.

Sethi S, Murphy T. Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review. *Clin Micr Rev* 2001; 14(2): 336-363.

Sethi S, Evans N, Brydon J et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 2002; 347: 465-471.

Sethi S, Wrona C, Grant B et al. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2004; 169(4):448-453.

Sethi S, File T. Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problem. *Curr. Med. Res. Opin*. 2004; 20:1511-1521.

Shahab L, Jarvis M, Britton J et al. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. *Thorax*. 2006; 61:1043-1047.

Sin D, Anthonisen N, Soriano J et al. Mortality in COPD: role of comorbidities. *Eur Respir J* 2006; 28: 1245–1257.

Sinden N, Stockley R. Systemic inflammation and comorbidity in COPD: result of "overspill" of inflammatory mediators from the lungs? Review of evidence. *Thorax* 2010; 65: 930-936.

Smyth L, Starkey C, Vestbo J et al. CD4 Regulatory Cells in COPD patients. *Chest* 2007; 132: 156-163.

Soler N, Torres A, Ewig S et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. *Am J Respir Crit Care Med.* 1998; 157: 1498-1505.

Soler N, Ewig S, Torres A et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. *Eur Respir J* 1999; 14(5): 1015-1022.

Soler-Cataluna J,Martinez-Garcia M, Roman Sanchez P et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax* 2005; 60: 925-931.

Sparrow D, Glyn R, Cohen M et al. The relationship of the peripheral leucocyte count and cigarette smoking to pulmonary function among adult men. *Chest* 1984; 86: 383-386.

Spencer S, Calverley P, Burge P et al. Health status deterioration in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001; 163: 122-128.

Spencer S, Calverley P, Burge P et al. Impact of preventing exacerbations on deterioration of health statrus in COPD. *Eur Respir J* 2004; 23:1-5.

Straelin K, Tornqvist E, Kaltoft M et al. Etiologic diagnosis of Adult Bacterial Pneumonia by Culture and PCR Applied to Respiratory Tract Samples. *J Clin Microbiol* 2006; 44: 643-645. (a).

Straelin K, Korsgaard J, Olce P et et al. Evaluation of multiplex PCR for bacterial pathogens applied to bronchoalveolar lavage. *Eur Respir J* 2006; 28: 568–575.

Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formeterol in the management of chronic obstructive pulmonary disease. *Eur Respir J* 2003; 21: 748-751.

Tan W, Xiang X, Qiu D et al. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. *Am J Med.* 2003; 115(4): 272-277.

Tashkin D, Celli B, Senn s et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med.* 2008; 359(15): 1543-1554.

Terada K, Muro S, Sato S et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. *Thorax.* 2008; 63(11):951-955.

Tsoumakidou M, Tzanakis N, Chrysofakis G et al. Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. *Respir Med*. 2005; 99(5): 572-579.

Turato G, Zuin R, Miniati M et al. Airway Infalmmation in Severe Chronic Obstructive Pulmonary Disease. Relationship with Lung Function and Radiologic Emphysema. *Am J Resp Crit Care Med* 2002; 166: 105-110.

Turner MC, Chen Y, Krewski D et al. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. *Am J Respir Crit Care Med*. 2007; 176(3): 285-90.

Van Eeden S, Hogg J. The response of human bone marrow to chronic cigarette smoking. *Eur Respir J.* 2000; 15: 915-921.

Vestbo J, Prescott E, Almdal T et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample. *Am J Respir Crit Care Med* 2006; 173:79–83.

Wagner P. Possible mechanisms underlying the development of cachexia in COPD. *Eur Respir J* 2008; 31: 492–501.

Washko GR, Fan VS, Ramsey SD et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbatins. *Am J Respir Crit Care Med.* 2008; 177(2):164-169.

Watz H, Waschki B, Kirsten A et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. *Chest* 2009; 136(4): 1039-1046.

Wedzicha J, Seemungal T, MacCallum P et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6. *Thromb Haemost* 2000; 84: 210-215.

Wedzicha J, Calverley P, Seemungal T et al. The Prevention of Chronic Obstructive Pulmoary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide. *Am J Respir Crit Care Med.* 2008; 177(1): 19-26.

Weiss S, Segal M, Sparrow D et al. Relation of FEV_1 and peripheral blood leukocyte count to total mortality: the normative aging population. *Am J Epidemiol* 1995; 142: 493-498.

White A, Gompertz S, Bayley D et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. *Thorax* 2003; 58: 680-685.

Wilson D, Yen-Lieberman B, Reischl U et al. Comparison of Five Methods for Extraction of Legionella pneumophila from Respiratory Specimens. *J Clin Microbiol* 2004; 42: 5913-5916.

Wilson I. Inhibition and Facilitation of Nucleic Acid Amplification. *Appl Environ Microbiol*. 1997; 63(10): 3741-3751.

Wilson R, Robers D, Cole P. Effect of bacterial products on human ciliary function in vitro. *Thorax* 1985; 40: 125-131.

Wilson R, Dowline R, Jackson a. The biology of bacterial colonization and invasion of the respiratory mucosa. *Eur Respir J* 1996; 9: 1523-1530.

Wilkinson TM, Patel IS, Wilks M et al. Airway bacterial load and FEV_1 decline in patients with chronic obstructive pulmonary disease. *Am J Resp Crit Care Med*. 2003; 167: 1090-1095.

Wilkinson T, Gavin C, Hurst J et al. Early Therapy Improves Outcomes of Exacerbations of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2004; 169: 1298-1303.

Wilkinson T, Donaldson G, Johnston S et al. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2006; 15:173(8):871-876. (a)

Wilkinson T, Hurst J, Perera W et al. Effect of Interactions Between Lower Airway Bacterial and Rhinoviral Infection in Exacerbations of COPD. *Chest* 2006; 129:317-324. (b)

Wouters E. Economic analysis of the Confronting COPD Survey: an overview. *Respir Med* 2003; 97: S3-S14.

Yamamto C, Yoneda T, Yoshikawa M et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. *Chest* 1997; 112: 505-510.

Zalacin R, Sobradillo V, Amilibia J et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. *Eur Respir J* 1999; 13: 343-348.

Zheng J, Kang J, Huang SGet al. Effect of Carbocisteine on acute exacerbation chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. *Lancet* 2008; 371: 2013-2018.

Zhu X, Gadgil A, Givelber R et al. Peripheral T cell Functions Correlate with the Severity of Chronic Obstructive Pulmonary Disease. *J Immunol* 2009; 182: 3270-3277.

References

Books:

Abbas AK and Lichtman AH. Cellular and Molecular Immunology. 5th Edition. Sauders 2003.

Burrow GL and Feltham RK. Cowan Steel's manual for the identification of medical bacteria. 3rd Edition. Cambridge University Press 1993.

Websites:

World Health Organisation Website:
http://www.who.int/whosis/whostat/2008/en/index.html

Gold Guidelines Website:
http://www.goldcopd.com/guidelinesresources.asp?l1=2&l2=0

NICE COPD Guidelines Website:
http://www.nice.org.uk/nicemedia/live/13029/49397/49397.pdf